GWP42003-P 20 mg/kg/day Dose

DRUG4 trials

Sponsors

Jazz Pharmaceuticals

Conditions

Dravet SyndromeEpilepsyLennox-Gastaut Syndrome

Phase 2

A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)

CompletedNCT02091206

Jazz PharmaceuticalsDravet Syndrome, Epilepsy

Start: 2014-10-22End: 2015-03-09Updated: 2022-09-28

A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol

CompletedNCT02565108

Jazz PharmaceuticalsEpilepsy

Start: 2016-01-20End: 2016-07-21Updated: 2022-09-28

Phase 3

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

CompletedNCT02091375

Jazz PharmaceuticalsDravet Syndrome, Epilepsy

Start: 2015-03-30End: 2015-11-26Updated: 2022-09-28

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

CompletedNCT02224690

Jazz PharmaceuticalsEpilepsy, Lennox-Gastaut Syndrome

Start: 2015-04-28End: 2016-03-18Updated: 2022-09-28

Related Papers

Cannabidiol (CBD) in the Therapy of Dravet and Lennox-Gastaut Syndromes – Efficacy and Safety of Epidyolex

Farmacja Polska2025-12-05

Clinically Meaningful Reduction in Drop Seizures in Patients with Lennox-Gastaut Syndrome Treated with Cannabidiol: Post Hoc Analysis of Phase 3 Clinical Trials.

2025-08-07

Add‐on cannabidiol in patients with Dravet syndrome: Results of a long‐term open‐label extension trial

Epilepsia2021-08-1886 citations

Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials

Epilepsia2021-07-1529 citations

Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials

Epilepsia2021-04-0257 citations

Time to Onset of Efficacy of Cannabidiol (CBD) During Titration in Patients with Lennox-Gastaut Syndrome or Dravet Syndrome Enrolled in Three Randomised Controlled Trials

Neuropediatrics2019-09-011 citations

Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Lennox-Gastaut Syndrome in an Open-label Extension Trial (GWPCARE5)

Neuropediatrics2019-09-01

Time to Onset of Efficacy of Cannabidiol (CBD) During Titration in Patients with Lennox-Gastaut Syndrome and Dravet Syndrome Enrolled in Three Randomized Controlled Trials (S48.009)

Neurology2019-04-091 citations

Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Lennox Gastaut Syndrome in an Open-label Extension Trial (GWPCARE5) (P5.5-001)

Neurology2019-04-09

Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.

2019-02-1190 citations

Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial

Epilepsia2018-12-23265 citations

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.

2018-01-26563 citations

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

New England Journal of Medicine2017-05-241607 citations